Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (3,995,271)	$ (7,960,429)
Net income (loss) from discontinued operations	(31,992)	(2,196,405)
Net loss from continuing operations	(3,963,279)	(5,764,024)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	86,988	386,847
Interest expense - OID	121,080
Share based compensation, net	3,562	90,569
Loss on disposition or impairment of assets		3,642,799
Bad debt expense (recovery)		61,599
Changes in operating assets and liabilities:
Accounts receivable	(41,700)	1,083,371
Prepaid expenses and other current assets	(115,584)	(2,772)
Security deposits		149,937
Right of use lease liability		(232,014)
Accounts payable and accrued expenses	1,915,698	(60,611)
Patient deposits		(116,452)
Net cash provided (used) in operating activities from continuing operations	(1,993,235)	(760,751)
Net cash provided (used) in operating activities from discontinued operations	(31,992)	(2,196,404)
Net cash used in operating activities	(2,025,227)	(2,957,156)
Cash flows from investing activities:
Proceeds from sale of Chicago		80,000
Proceeds from sale of fixed assets		1,050,000
Note receivable	(375,000)	(3,000,000)
Net cash used in investing activities	(375,000)	(1,870,000)
Cash flows from financing activities:
Proceeds from issuance of common stock		64,032
Proceeds from issuance of preferred stock, net of offering costs	975,951	4,300,000
Payments on notes payable		(60,599)
Proceeds from notes payable	1,400,000
Payments on finance lease obligation	(1,724)	(14,842)
Net cash provided in financing activities	2,374,227	4,288,591
Net increase (decrease) in cash	(26,000)	(538,565)
Cash, beginning of period	221,511	763,211
Cash, end of period	195,511	224,646
Supplemental cash flow information:
Interest paid		96,656
Income tax
Non-cash investing and financial activities:
Preferred stock conversion	2
Accrued dividends	1,161,000	55,000
Settlement of notes receivable in connection with asset purchase agreement	$ 1,083,000